Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This is a multicentric, double-blind, placebo-controlled, randomized, parallel group study to
estimate the effect of minocycline as add-on to interferon beta-1a (IFN beta-1a) in subjects
with relapsing-remitting multiple sclerosis (RRMS).